FDA Approves Roivant's LISRAYA as First Targeted Therapy for Dermatomyositis
ROIV has more than doubled off its 52-week low of $11.85.
Summary
Roivant's LISRAYA received FDA approval as the first targeted therapy for dermatomyositis, with immediate U.S. commercial availability and compelling Phase 3 efficacy data showing significant steroid-sparing benefits.
Key Events · Product Development and Regulatory · ROIV
-
FDA Approves LISRAYA for Dermatomyositis
LISRAYA (brepocitinib) 30 mg received FDA approval as the first and only targeted therapy for adults with dermatomyositis, a rare systemic autoimmune disease. The drug is available immediately in the U.S.
-
Phase 3 VALOR Efficacy Data
55% of LISRAYA patients achieved moderate or better improvement on Total Improvement Score with minimal/no steroid use vs 30% on placebo. 45% came off corticosteroids entirely vs 29% on placebo.
-
Commercial Launch Underway
LISRAYA is available through a limited distribution network of specialty pharmacies. The My Compass Support program offers eligible patients $0/month copay assistance.
-
Investor Call Scheduled
Roivant will host an investor conference call on August 28, 2026 at 8:00 a.m. ET to discuss the approval and commercial strategy.
Analysis · ROIV · Life Sciences
The FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis — the first targeted therapy ever approved for this rare autoimmune disease. The drug is available immediately in the U.S., converting Roivant from a clinical-stage pipeline story into a commercial-stage company with a first-in-class product. Phase 3 VALOR data showed 55% of patients achieved meaningful improvement with minimal steroid use versus 30% on placebo, and 45% came off corticosteroids entirely. This approval validates the brepocitinib platform and opens a path for expansion into non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris. The company will host an investor call tomorrow morning to discuss commercial strategy.
How filings like this one have moved
In the 30 days to Aug 27, 2026, 42.6% of the 975 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.06%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $37.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.1B. The 52-week trading range was $11.85 to $37.97. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.